Interleukin 1 secretion from human alveolar macrophages in lung disease.

Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

Interleukin 1 secretion from human alveolar macrophages in lung disease.

J Clin Immunol. 1986 Jul;6(4):326-33. Unique Identifier : AIDSLINE MED/86304869
Eden E; Turino GM

Abstract: Interleukin 1 secretion from human alveolar macrophages was studied in patients with interstitial pulmonary fibrosis, sarcoidosis, and the acquired immunodeficiency syndrome with pneumonitis and compared to secretion from alveolar macrophages of normal volunteers. Macrophages lavaged from the lungs were stimulated with 10 micrograms/ml of lipopolysaccharide and cultured for 24 hr. In some cases macrophages were also stimulated with 1 microgram/ml lipopolysaccharide. After dialysis of the culture supernatants, interleukin 1 secretion was quantified by the thymocyte proliferation assay and probit analysis and expressed in terms of secretion from 1 million macrophages. Results showed that, on average, macrophages derived from patients secreted more interleukin 1 after stimulation with lipopolysaccharide compared to normal subjects. Mean secretion was significantly greater from macrophages of patients with acquired immunodeficiency syndrome and interstitial pulmonary fibrosis when stimulated with 10 micrograms/ml lipopolysaccharide. Of the 24 individuals studied, spontaneous interleukin 1 secretion was detected from unstimulated macrophages in only 1 patient and 1 normal volunteer. We conclude that alveolar macrophages lavaged from the lungs of patients with inflammatory lung disease have an increased capacity to secrete interleukin 1 on in vitro stimulation with lipopolysaccharide. Possible mechanisms for this increase are discussed.

Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS Adult Animal Comparative Study Female Granuloma/IMMUNOLOGY Human Interleukin-1/PHARMACOLOGY/*SECRETION Lipopolysaccharides/PHARMACOLOGY Lung Diseases/*IMMUNOLOGY Macrophage Activation/DRUG EFFECTS Macrophages/*SECRETION Male Mice Mice, Inbred C3H Pneumonia, Pneumocystis carinii/COMPLICATIONS/*IMMUNOLOGY Pulmonary Alveoli/PATHOLOGY Pulmonary Fibrosis/*IMMUNOLOGY Sarcoidosis/*IMMUNOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. T-Lymphocytes/DRUG EFFECTS JOURNAL ARTICLE

861230
M86C0156

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .